%0 Journal Article %T The Expression of Leptin and Its Receptor During Tumorigenesis of Diffuse Gliomas such as Astrocytoma and Oligodendroglioma - Grade II, III and IV (NOS) %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Vokuda, Ramya S %A B H, Srinivas %A Madhugiri, Venkatesh S %A Velusamy, Saravana Kumar %A Verma, Surendra Kumar %D 2019 %\ 02/01/2019 %V 20 %N 2 %P 479-485 %! The Expression of Leptin and Its Receptor During Tumorigenesis of Diffuse Gliomas such as Astrocytoma and Oligodendroglioma - Grade II, III and IV (NOS) %K immunohistochemistry %K Brain tumors %K Real-Time PCR %R 10.31557/APJCP.2019.20.2.479 %X Background: Leptin, an adipocytokine functions via the leptin receptor, OB-Rb that contains an intact intracellulardomain and activates the JAK/STAT signalling cascade. It stimulates growth, migration and invasion of cancer cells invitro potentiating angiogenesis. Recently, the involvement of leptin in tumor progression is being explored. Gliomasexhibit poor prognosis, low survival rates demanding for novel therapeutic regimens resulting in discovery of manypotential biomarkers and pharmaceutical targets. We analysed the potential role of leptin and OB-Rb in carcinogenesisof malignant gliomas. Methods: Sixty fresh tissue samples of diffuse gliomas were collected after tumor excision. Realtime PCR, immunohistochemical (IHC) analysis and western blot analysis were carried out to assess the expression ofleptin and its receptor. Results: The present study demonstrates the expression of leptin and LepR and their involvementin tumor progression. Of the 60 cases, 57 cases (95%) and 53 cases (88.3%) showed amplification for leptin andOB-Rb respectively. The expression of these proteins were measured semi-quantitatively and correlated with degree ofmalignancy (p<0.05). The bands were visualised on western blot. Conclusion: Leptin may be valued as a pharmaceuticaltarget and anti-leptin compounds could be developed as drugs in mono- or combined therapies for these tumors. %U https://journal.waocp.org/article_82366_f701b6c2f0144f20badfd535675298af.pdf